Good performance by Shire in Q3 19, largely in line with our expectations. Product sales grew by 7% at CER to $3.75bn, led by a 13% growth in the immunology business, followed by 7% in neuroscience and 9% in genetic diseases, offset partly by a negative impact of 1pp due to the divestment of the oncology business. NB All sales growth numbers at CER, unless specified otherwise. Royalty income declined by 27%, primarily as some of the royalties expired and the Adderall XR contribution was recla
23 Nov 2018
Strong Q3 as it inches towards deal closure
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q3 as it inches towards deal closure
Shires Income PLC GBP (SHRS:LON) | 224 2.2 0.4% | Mkt Cap: 92.9m
- Published:
23 Nov 2018 -
Author:
Kamla Singh -
Pages:
3
Good performance by Shire in Q3 19, largely in line with our expectations. Product sales grew by 7% at CER to $3.75bn, led by a 13% growth in the immunology business, followed by 7% in neuroscience and 9% in genetic diseases, offset partly by a negative impact of 1pp due to the divestment of the oncology business. NB All sales growth numbers at CER, unless specified otherwise. Royalty income declined by 27%, primarily as some of the royalties expired and the Adderall XR contribution was recla